Editorial Board About Us

Bob Djavan

All articles from this author are listed below.

Volume 6, Number 1 Meeting Reviews

New Findings in Prostate Cancer, Benign Prostatic Hyperplasia, and Sexual Dysfunction

Highlights from the XVIII Congress of the European Association of Urology

Mesut Remzi Bob Djavan

Prostate cancer Prostate-specific antigen Radical prostatectomy Nomogram Benign prostatic

Volume 7, Number 4 Review Articles

Dutasteride: A Review of Current Data on a Novel Dual Inhibitor of 5a Reductase

Treatment Update

Mike Harik Sibylle Marihart Bob Djavan

Benign prostatic hyperplasia Prostate volume Efficacy

Volume 7, Number 1 Meeting Reviews

What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?

Yan Kit Fong Mesut Remzi Theodore Anagnostou Michael Dobrovits Amir Kaisary Bob Djavan

Prostate cancer Benign prostatic hyperplasia Medical treatment Surgical treatment Minimally invasive surgery Percutaneous surgery

Volume 7, Number 1 Literature Reviews

Prostate Cancer

Yan Kit Fong Bob Djavan

Volume 8, Number 1 Review Articles

Chemopreventative Trials in Urologic Cancer

Treatment Review

Vahagn R Ashughyan Sibylle Marihart Bob Djavan

Prostate Bladder Chemoprevention Finasteride Cancer Nutritional supplements Dutasteride

Volume 9, Number 4 Meeting Reviews

New Findings in Bladder and Prostate Cancer

Meeting Review

Maximilian Rom Franklin E Kuehhas Bob Djavan

Highlights of the 22nd Annual Congress of the European Association of Urology, March 21-24, 2007, Berlin, Germany [Rev Urol. 2007;9(4):214-219]

Prostate cancer Bladder cancer Transitional cell carcinoma Prostate biopsy Human kallikrein Urothelial tumors Laparoscopic radical prostatectomy

Volume 10, Number 4 Meeting Reviews

New Findings in Prostate Cancer

Meeting Review

Bob Djavan Franklin E Kuehhas

Highlights from the 23rd Annual Congress of the European Association of Urology, March 26–29, 2008, Milan, Italy [Rev Urol. 2008;10(4):290-293]

Quality of life Pelvic lymphadenectomy Prostate cancer, cT3 Prognostic factors Dynamic contrast-enhancedmagnetic resonance imaging Postoperative urinary continence

Volume 10, Number 4 Literature Reviews

Prostate Cancer: Androgen Deprivation Therapy

News and Views from the Literature

Paul Hoffman Bob Djavan

[Rev Urol. 2008;10(4):305-306]

Volume 10, Number 2 Review Articles

Prostate Cancer in Elderly Men

Treatment Update

Anton Stangelberger Matthias Waldert Bob Djavan

Due to increasing life expectancy and the introduction of prostate-specific antigen (PSA) screening, a rising number of elderly men are diagnosed with prostate cancer. Besides PSA serum levels and Gleason score, age is considered to be a key prognostic factor in terms of treatment decisions. In men older than 70 years, treatment without curative intent may deprive the frail patient of years of life. Modern radical prostatectomy techniques are associated with low perioperative morbidity, excellent clinical outcome, and documented long-term disease control. Thus, radical prostatectomy should be considered because local treatment of organ-confined prostate cancer potentially cures disease. The huge extent of PSA screening programs may lead to overdiagnosis of prostate cancer. Not every man who is diagnosed with prostate cancer will develop clinically significant disease. This has led to the concept of expectant management for screen-detected, small-volume, low-grade disease, with the intention of providing therapy for those men with disease progression. [Rev Urol. 2008;10(2):111-119]

Prostate cancer Elderly men Screening Quality of life Prostate-specific antigen Overtreatment